Published in Cancer Res on December 15, 1991
The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol (2012) 1.87
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol (1995) 1.17
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer (1997) 1.15
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia (2010) 1.08
Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol (1996) 1.05
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer (1996) 0.98
Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer (2012) 0.98
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol (1995) 0.97
Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer (1995) 0.97
Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer (1995) 0.88
O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer (1992) 0.87
DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner. Int J Colorectal Dis (2011) 0.86
Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. Mol Cell Biol (2000) 0.85
Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer (2006) 0.83
Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy. Br J Cancer (1997) 0.81
Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br J Cancer (1997) 0.80
Mechanisms regulating resistance to inhibitors of topoisomerase II. Front Pharmacol (2013) 0.80
Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol (1994) 0.78
Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. J Clin Pathol (2001) 0.78
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. Br J Cancer (2003) 0.78
Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma. J Clin Pathol (1997) 0.77
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One (2014) 0.76
Inhibition of DNA Topoisomerase Type IIα (TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study. Biomed Res Int (2016) 0.76
Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression. PLoS One (2015) 0.76
Sulfonoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo. Sci Rep (2015) 0.75
Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases. Curr Genomics (2017) 0.75
Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br J Cancer (1995) 0.75
Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα. Mol Clin Oncol (2015) 0.75
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. Br J Cancer (1998) 0.75
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
The Bloom's syndrome gene product promotes branch migration of holliday junctions. Proc Natl Acad Sci U S A (2000) 4.67
The Bloom's syndrome helicase unwinds G4 DNA. J Biol Chem (1998) 4.67
SGS1, a homologue of the Bloom's and Werner's syndrome genes, is required for maintenance of genome stability in Saccharomyces cerevisiae. Genetics (1996) 4.62
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
The Bloom's and Werner's syndrome proteins are DNA structure-specific helicases. Nucleic Acids Res (2001) 4.47
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
Sgs1: a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation. Cell (1995) 4.08
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost (2014) 3.90
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol (2000) 3.57
The Bloom's syndrome gene product interacts with topoisomerase III. J Biol Chem (2000) 3.52
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
The Bloom's syndrome gene product is a 3'-5' DNA helicase. J Biol Chem (1997) 3.32
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Replication protein A physically interacts with the Bloom's syndrome protein and stimulates its helicase activity. J Biol Chem (2000) 3.17
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51. J Biol Chem (2001) 3.05
Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol (2001) 2.98
Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res (1991) 2.96
Werner's syndrome protein (WRN) migrates Holliday junctions and co-localizes with RPA upon replication arrest. EMBO Rep (2000) 2.88
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol (1993) 2.73
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Defending genome integrity during DNA replication: a proposed role for RecQ family helicases. Bioessays (1999) 2.71
XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J (2001) 2.67
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Modified eggs are compatible with a diet that reduces serum cholesterol concentrations in humans. J Nutr (1992) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. EMBO J (1997) 2.53
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis (1989) 2.21
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18
Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08
An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Isolation of cDNA clones encoding an enzyme from bovine cells that repairs oxidative DNA damage in vitro: homology with bacterial repair enzymes. Nucleic Acids Res (1991) 2.03
The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect (2001) 2.03
Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03
Oligomeric ring structure of the Bloom's syndrome helicase. Curr Biol (1999) 2.01
The E. coli uvrD gene product is DNA helicase II. Mol Gen Genet (1983) 1.99
Structure and function of apurinic/apyrimidinic endonucleases. Bioessays (1995) 1.98
RecQ family helicases: roles in cancer and aging. Curr Opin Genet Dev (2000) 1.98
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res (1986) 1.94
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90
Cloning and characterization of a functional human homolog of Escherichia coli endonuclease III. Proc Natl Acad Sci U S A (1997) 1.89
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. Hum Mol Genet (2001) 1.86
Mechanism of stimulation of the DNA glycosylase activity of hOGG1 by the major human AP endonuclease: bypass of the AP lyase activity step. Nucleic Acids Res (2001) 1.86
Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res (1996) 1.79
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
Identification of the Escherichia coli recB and recC gene products. Nature (1981) 1.75
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Structure and function of type II DNA topoisomerases. Biochem J (1994) 1.73
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol (2001) 1.72
DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res (1986) 1.72
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe. Nucleic Acids Res (1999) 1.71
Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol (2000) 1.71
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
Gating of gap junction channels. Biophys J (1984) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70